CN111450089A - Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 - Google Patents
Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 Download PDFInfo
- Publication number
- CN111450089A CN111450089A CN202010530779.3A CN202010530779A CN111450089A CN 111450089 A CN111450089 A CN 111450089A CN 202010530779 A CN202010530779 A CN 202010530779A CN 111450089 A CN111450089 A CN 111450089A
- Authority
- CN
- China
- Prior art keywords
- melanoma
- bepridil
- drugs
- pharmaceutical composition
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000001441 melanoma Diseases 0.000 title claims abstract description 67
- 239000003814 drug Substances 0.000 title claims abstract description 55
- WGIKEBHIKKWJLG-UHFFFAOYSA-N methanesulfonic acid;2-[4-[(4-nitrophenyl)methoxy]phenyl]ethyl carbamimidothioate Chemical compound CS(O)(=O)=O.C1=CC(CCSC(=N)N)=CC=C1OCC1=CC=C([N+]([O-])=O)C=C1 WGIKEBHIKKWJLG-UHFFFAOYSA-N 0.000 title claims abstract description 54
- UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 229960003665 bepridil Drugs 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 26
- 102000001794 Sodium-Calcium Exchanger Human genes 0.000 claims abstract description 10
- 108010040240 Sodium-Calcium Exchanger Proteins 0.000 claims abstract description 10
- 239000003112 inhibitor Substances 0.000 claims abstract description 10
- 239000002246 antineoplastic agent Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 229940044683 chemotherapy drug Drugs 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims description 3
- KZMAWJRXKGLWGS-UHFFFAOYSA-N 2-chloro-n-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]-n-(3-methoxypropyl)acetamide Chemical compound S1C(N(C(=O)CCl)CCCOC)=NC(C=2C=CC(OC)=CC=2)=C1 KZMAWJRXKGLWGS-UHFFFAOYSA-N 0.000 claims description 3
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims description 3
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims description 3
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 229960002465 dabrafenib Drugs 0.000 claims description 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003901 dacarbazine Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims description 3
- 229960003301 nivolumab Drugs 0.000 claims description 3
- 229960002621 pembrolizumab Drugs 0.000 claims description 3
- 150000003384 small molecules Chemical class 0.000 claims description 3
- 229960004964 temozolomide Drugs 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 229960004066 trametinib Drugs 0.000 claims description 3
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960003862 vemurafenib Drugs 0.000 claims description 3
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims description 3
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 2
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 claims description 2
- 229960005243 carmustine Drugs 0.000 claims description 2
- 229960004783 fotemustine Drugs 0.000 claims description 2
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 claims description 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 2
- 229960002247 lomustine Drugs 0.000 claims description 2
- 229960000485 methotrexate Drugs 0.000 claims description 2
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 claims description 2
- 229960001420 nimustine Drugs 0.000 claims description 2
- 230000000174 oncolytic effect Effects 0.000 claims description 2
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 claims description 2
- 229960000624 procarbazine Drugs 0.000 claims description 2
- 230000035945 sensitivity Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000004083 survival effect Effects 0.000 abstract description 14
- 206010059866 Drug resistance Diseases 0.000 abstract description 5
- 210000004881 tumor cell Anatomy 0.000 abstract description 5
- 230000002147 killing effect Effects 0.000 abstract description 4
- 230000007246 mechanism Effects 0.000 abstract description 3
- 239000002547 new drug Substances 0.000 abstract description 2
- 238000004393 prognosis Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 33
- 241000699670 Mus sp. Species 0.000 description 17
- 238000000034 method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 210000003491 skin Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 244000215068 Acacia senegal Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000006285 cell suspension Substances 0.000 description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 240000001624 Espostoa lanata Species 0.000 description 2
- 235000009161 Espostoa lanata Nutrition 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003127 anti-melanomic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 210000003194 forelimb Anatomy 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 230000004565 tumor cell growth Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000012766 Growth delay Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 208000007256 Nevus Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229960002576 amiloride Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000001964 calcium overload Effects 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 201000003731 mucosal melanoma Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 208000028412 nervous system injury Diseases 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 244000309459 oncolytic virus Species 0.000 description 1
- 239000008183 oral pharmaceutical preparation Substances 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
本发明涉及生物医药技术领域,具体是Bepridil或KB‑R7943在制备治疗黑色素瘤的药物中的应用。本发明提出了抗黑色素瘤的新策略,即应用钠钙交换体的抑制剂Bepridil或KB‑R7943治疗黑色素瘤,属于老药新用。本发明研究Bepridil或KB‑R7943杀灭肿瘤细胞的机制与以往的药物完全不同,也没有产生耐药性。这两个新药的使用有望改善黑色素瘤患者的预后和提高患者生存率,减轻社会负担,为黑色素瘤的治疗带来光明前景。
Description
技术领域
本发明涉及生物医药技术领域,具体地说,是Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用。
背景技术
黑色素瘤是由起源于神经脊的黑素细胞发展而来的恶性肿瘤,多数由正常的痣和色素斑演变形成,多发于皮肤。此外,黑色素细胞也存在于皮肤细胞外,如黏膜型黑色素瘤常发生于头颈部的鼻窦、口腔、肛门、外阴和阴道,也出现在胃肠道和泌尿生殖道之间的黏膜。50%~80%的晚期黑色素瘤患者会发生肝转移,8%~46%的黑色素瘤患者会发生脑转移,发生转移的晚期黑色素瘤中位生存时间仅为8~9个月,黑色素瘤一度被称为“癌王”。
恶性黑色素瘤好发于白色人种,西方人黑色素瘤多分布在皮肤浅表(称为皮肤型),而我国黑色素瘤主要分布于四肢末端(称为肢端型)和黏膜(称为黏膜型),中国黑色素瘤恶性程度和死亡率较西方更高。我国的黑色素瘤占所有恶性肿瘤的1%~3%,发病率逐年增长,年增长率为3%~5%。在我国,由于人口基数大,恶性黑色素瘤的总体罹患人数较多,尤其在沿海发达城市,恶性黑色素瘤的发病率和死亡率均呈现快速上升趋势,应引起足够的重视。
目前治疗黑色素瘤的药物主要有化学治疗药物达卡巴嗪、替莫唑胺,生物治疗药威罗菲尼、达拉菲尼、曲美替尼、易普利姆玛、nivolumab和pembrolizumab,小分子靶向药物BRAF抑制剂、MEK抑制剂、作用于程序性死亡分子1(PD-1)的免疫治疗药物以及溶瘤病毒疗法。这些治疗药物和治疗手段尽管能不同程度的提高患者的应答率和总生存率,但是仍面临着诸如不良反应较为明显、单靶点药物易产生免疫逃逸和耐药性、治疗效果并不理想等问题。抗黑色素瘤之路仍存挑战,需要进一步研发新的分子靶向药和新型化疗药物,解决黑色素瘤的药物治疗难题。
Bepridil和KB-R7943的分子式、化学结构如附图1所示。Bepridil的中文名是苄普地尔,是一种临床上正在使用的心血管药物,Bepridil的药理学作用主要是抑制钠钙交换体(NCX)和抑制钙离子慢通道,临床上用于治疗心绞痛、各种心律失常和高血压。KB-R7943的药理作用是抑制细胞膜上的钠钙交换体(Na+/Ca2+exchanger,NCX),目前还没有临床使用的报道,动物实验显示KB-R7943有抗心律失常和保护心肌缺血的作用。
中国专利201711398885.5公开了KB-R7943或Bepridil在制备治疗神经胶质瘤中的应用发明。另外,中国专利201380079011.7公开了用于减轻神经系统损伤的组合物及该组合物,其具体公开一种用于减轻受治者神经损伤的方法,包括:向所述受治者施用治疗有效量的包含阿米洛利、阿米洛利类似物或它们的药学上可接受的盐的药物组合物,其中,所述阿米洛利类似物包括KB-R7943。
现有技术中,关于化合物Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用,目前还未见报道。
发明内容
本发明的目的是针对现有技术中的不足,提供钠钙交换体抑制剂Bepridil或KB-R7943的制药新用途。
本发明的再一的目的是针对现有技术中的不足,提供一种治疗黑色素瘤的药物组合物。
为实现上述目的,本发明采取的技术方案是:
钠钙交换体抑制剂Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用。
作为本发明的一个优选实施方案,所述药物的活性成分为Bepridil。
作为本发明的一个优选实施方案,所述药物的活性成分为KB-R7943。
作为本发明的一个优选实施方案,所述药物单独使用或者以药物组合物的形式使用;所述药物组合物包含治疗有效量的Bepridil或KB-R7943,也可以同时包含Bepridil和KB-R7943,以及黑色素瘤常规化疗药物。
作为本发明的一个优选实施方案,把Bepridil或KB-R7943与其他常规化疗药物合并使用,可以增强黑色素瘤对其他常规化疗药物的敏感性。
所述黑色素瘤治疗药物和方法包括但不限于:化学治疗药物达卡巴嗪、替莫唑胺、尼莫斯汀、卡莫斯汀、洛莫斯汀、甲基苄肼、甲氨喋呤或福莫司汀,生物治疗药威罗菲尼、达拉菲尼、曲美替尼、易普利姆玛、nivolumab和pembrolizumab,小分子靶向药物BRAF抑制剂、MEK抑制剂、作用于程序性死亡分子1(PD-1)的免疫治疗药物以及溶瘤病毒疗法。
为实现上述第二个目的,本发明采取的技术方案是:
一种治疗黑色素瘤的药物组合物,所述药物组合物包含治疗有效量的Bepridil或KB-R7943,也可以同时包含KB-R7943和Bepridil,以及药学上可接受的载体。
所述药学上可接受的载体包括但并不限于:盐水、缓冲液、葡萄糖、水、甘油、乙醇、稀释剂、润滑剂、粘合剂、崩解剂、甜味剂、湿润剂。
由于Bepridil和KB-R7943口服以后,通过血液循环到达黑色素瘤部位,因此包含本发明化合物的药物组合物可以根据现有技术常规方法制备固/液体口服药物制剂或静脉注射液。
固体口服形式的药物制剂可以包括稀释剂、润滑剂、粘合剂、崩解剂、甜味剂、湿润剂以及药物制剂中常用的无活性且无药理活性的物质。这些药物制剂可以以现有技术已知的方法进行制备。例如,通过混合、制粒、制片、糖包衣或膜包衣处理的方法,制备成胶囊剂、颗粒剂、片剂或合剂。示例性的稀释剂例如可以是:乳糖、右旋糖、二糖、蔗糖、纤维素、玉米淀粉或马铃薯淀粉;润滑剂可以是:硅石、滑石、硬脂酸、硬脂酸镁或钙和/或聚乙二醇;粘合剂可以是:淀粉类、阿拉伯胶、明胶、甲基纤维素、羧甲基纤维素或聚乙烯吡咯烷酮;崩解剂可以是:淀粉、海藻酸、海藻酸盐或淀粉羟乙酸钠;湿润剂可以是:卵磷脂、聚山梨酯和月桂硫酸盐(酯)。
液体口服形式的药物制剂可以是糖浆、乳剂或混悬液。糖浆可以包含作为载体的二糖,或者二糖和甘油和/或甘露醇和山梨糖醇。混悬液和乳剂可以包含作为载体例子的天然胶、琼脂、海藻酸钠、果胶、甲基纤维素、羧甲基纤维素或聚乙烯醇。
静脉注射剂形式,例如用生理盐水或含有葡萄糖和其他辅剂的水溶液通过常规方法进行制备。
所述治疗有效量,是指本发明化合物的施加量足以达到治疗预期目的量,其根据治疗前所期望的治疗效果实现。治疗有效量的确定是本领域技术人员的常规技术手段,有效量取决于多种因素,例如接受治疗个体的体型和/或个体所患疾病或不希望有的病症的发展程度。有效量也取决于药效化合物是否以单一剂量及用药频率。
本发明中的药物治疗个体,包括哺乳动物和非哺乳动物。哺乳动物的例子包括但不限于:哺乳动物类的任何成员,例如成年人、儿童、非人的灵长类猩猩,以及其他猿和猴类;农场动物例如牛、马、羊、山羊、猪;家畜类动物例如兔、狗和猫;实验室动物包括啮齿类,例如大鼠、小鼠和豚鼠等。非哺乳动物的例子包括但不限于,鸟、鱼等。
本发明提供的抗肿瘤药物能有效杀灭黑色素瘤细胞,目前没有产生耐药性和抗药性,药物作用靶点与既往药物不同,属于老药新用,有望给黑色素瘤的治疗带来光明前景。
在治疗黑色素瘤的过程中,本发明的药物可以单独使用,也可以与手术治疗合用,或与其他化疗药物合用,与放射性治疗方法合用,产生综合治疗效果。
本发明提供的抗肿瘤药物具有见效快、疗效好的优点,细胞实验和动物实验结果显示:化学物质Bepridil或KB-R7943对黑色素瘤细胞的生长都有抑制作用,这两个药物在较高浓度杀死黑色素瘤细胞,因此化合物Bepridil或KB-R7943都可用于制备治疗黑色素瘤的药物,改善黑色素瘤患者的预后和提高其生存率。
Bepridil和KB-R7943都是已知的化合物,本发明将钠钙交换体抑制剂Bepridil或KB-R7943应用到黑色素瘤的治疗,属于老药新用,有显著的创新性。
文献表明Bepridil或KB-R7943口服以后,进入血液循环和分布到全身,所以患者可以口服这两种药物,静脉注射也可以,用于治疗黑色素瘤。与现有的抗黑色素瘤药物相比较,Bepridil或KB-R7943作用于全新的药物靶点,即细胞膜上的钠钙交换体,杀灭肿瘤细胞的机制与以往的药物完全不同,目前也没有产生耐药性。
本发明优点在于:
本发明首次发现了钠钙交换体抑制剂的新用途,为黑色素瘤患者提供了新的治疗方案,通过实验结果表明:该药物与现有的抗黑色素瘤药物相比较,其杀灭肿瘤细胞的机制不同,该药物通过增加细胞内钙离子的浓度和诱发钙超载来杀死肿瘤细胞,且未产生耐药性,疗效好,实用性强,应用前景广。
附图说明
附图1是Bepridil和KB-R7943的分子式和化学结构。
附图2是Bepridil抑制黑色素瘤细胞系(A2058和A375)生长的剂量-效应曲线。
附图3是KB-R7943抑制黑色素瘤细胞系(A2058和A375)生长的剂量-效应曲线。
附图4是Bepridil(A图)和KB-R7943(B图)对在体黑色素瘤生长的抑制作用。
附图5是C57BL/J小鼠右前肢皮下种植B16黑色素瘤细胞后,记录对照组与药物治疗组的小鼠存活率,Bepridil和KB-R7943治疗组都比对照组显著延长了小鼠的生存时间。生存曲线整体比较的LogRank检验结果为P<0.05,每组15只动物。
具体实施方式
下面结合具体实施方式,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外应理解,在阅读了本发明记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本申请所附权利要求书所限定的范围。
实施例1细胞实验
1实验方法
用DMEM培养基+10%的胎牛血清培养人黑色素瘤细胞系A2058和A375。细胞以9000个/孔接种于96孔板,放入含有5%二氧化碳的37℃培养箱内培养。待细胞长到70%-80%后,在培养基中加入一系列不同浓度的Bepridil或KB-R7943,药物孵育2天以后测定细胞的死亡状况,采用CCK-8方法检测细胞活性。
2结果
结果发现Bepridil和KB-R7943都显著抑制黑色素瘤细胞的生长。Bepridil抑制肿瘤细胞生长的剂量-效应关系如图2所示,Bepridil剂量依赖性地杀死黑色素瘤细胞系A2058和A375(图2),通过拟合量效曲线和重复5次实验产生的50%抑制浓度(IC50)分别为:Bepridil抑制A2058细胞的IC50:17.1±0.89μM(微摩尔/升);Bepridil抑制A375细胞的IC50:16.9±0.96μM(微摩尔/升)。
KB-R7943抑制肿瘤细胞生长的剂量-效应关系如图3所示,
KB-R7943剂量依赖性地杀死黑色素瘤细胞系A2058和A375(图3),通过拟合量效曲线和重复5次实验产生的50%抑制浓度(IC50)分别为:KB-R7943抑制A2058细胞的IC50:20.9±2.38μM(微摩尔/升);KB-R7943抑制A375细胞的IC50:19.7±5.08μM(微摩尔/升)。
3结论
总之,我们通过体外细胞实验证明,Bepridil和KB-R7943对黑色素瘤细胞都有显著的杀灭作用,并且没有出现耐药性。
实施例2体内动物实验
1实验方法
1)小鼠黑色素瘤细胞系B16的培养和小鼠皮下种植模型的建立:
用RPMI-1640培养基+10%FBS培养小鼠黑色素瘤细胞系B16,置于37℃、含5%CO2的培养箱内传代生长。取对数生长期细胞,用PBS洗和0.25%胰酶消化,用PBS收集细胞制成细胞悬液,台盼蓝染色试验鉴定细胞存活率大于92%,调整细胞浓度为100000/μl后30分钟内种植到大鼠脑内,以下简述细胞种植过程。
黑色素瘤模型的建立:选取8月龄的雄性C57BL/6J小鼠,用异氟烷麻醉机进行全身麻醉后,以小鼠右侧后腋窝为中心剃除毛发,酒精棉球擦拭消毒后,左手用尖镊提起其中央皮肤,右手用31号针头注射器在其提起皮肤下方0.3厘米处缓慢注入小鼠黑色素瘤B16细胞悬液200μL,见皮下球囊状鼓起,放松尖镊并拔针,用无菌棉球轻轻按压穿刺处10秒钟。建立模型全程应防止苏醒,同时也要防止注入部位肿瘤细胞悬液的渗漏。种植后5-7天可见皮下隆起的肿瘤结界,证明小鼠黑色素瘤模型建模成功。
2)动物分组和药物治疗方案:
实验设计共四组小鼠:对照组一;Bepridil治疗组;对照组二;KB-R7943治疗组,每组各25只动物。所有小鼠均为种植B16细胞的黑色素瘤模型,种植后第6天开始分别接受KB-R7943和Bepridil治疗。KB-R7943和Bepridil配制方法是先用DMSO溶解,最后溶解于阿拉伯树胶水溶液(5%)。KB-R7943(30mg/kg)和Bepridil(30mg/kg)溶液每天一次给小鼠灌胃给药,连续给药治疗40天。对照组小鼠仅接受阿拉伯树胶溶液灌胃,灌胃的剂量和时间与治疗组相同。
3)动物实验的疗效观察:
黑色素瘤模型小鼠治疗开始后,每天测量肿瘤体积大小,测量到第20天。方法是利用游标卡尺测量肿瘤的最小直径(a)和最大直径(b),按V肿瘤体积=a2×b×π/6公式计算肿瘤体积,并记录肿瘤生长延迟效应,同时观察动物的生存情况。小鼠出现频死前症状或观察期满时(治疗40天)予以处死,生存曲线绘制应用Kaplan-Meier氏方法,统计学检验方法为Log-rank检验。
2实验结果:
结果如图4所示,C57BL/J小鼠右前肢皮下种植B16小鼠黑色素瘤细胞,5-7天后形成可见肿瘤结节。B16细胞种植后第6天开始进行药物治疗,对照组仅给予溶剂治疗。从第7天开始测量种植瘤的长、短径,连续测量至第20天。通过计算肿瘤体积发现,Bepridil和KB-R7943都能显著抑制种植黑色素瘤的生长(P<0.05,t检验,每组动物数n=10)。
结果如图5所示,发现对照组小鼠在第17-19天开始出现死亡,第37天时死亡率达到100%;而Bepridil和KB-R7943治疗组在第22-25天出现死亡,46-49天时死亡率达到100%。应用Kaplan-Meier氏方法绘制的生存曲线,经Log-Rank检验后发现,Bepridil和KB-R7943治疗组都比对照组显著延长了小鼠的生存时间(P<0.05,每组动物数n=15)。
3结论
针对小鼠皮下种植黑色素瘤细胞的动物模型,采取灌胃给药的方法分别给予Bepridil和KB-R7943进行药物治疗,结果发现Bepridil和KB-R7943均能显著抑制黑色素瘤的生长,并且均能显著延长荷瘤小鼠的生存时间。体内动物实验证明Bepridil和KB-R7943对黑色素瘤有治疗作用。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员,在不脱离本发明原理的前提下,还可以做出若干改进和补充,这些改进和补充也应视为本发明的保护范围。
Claims (7)
1.钠钙交换体抑制剂在制备治疗黑色素瘤的药物中的应用。
2.根据权利要求1所述的应用,其特征在于,所述的钠钙交换体抑制剂是Bepridil和/或KB-R7943。
3.根据权利要求1所述的应用,其特征在于,所述的药物的活性成分为Bepridil和/或KB-R7943。
4.根据权利要求1所述的应用,其特征在于,所述的药物单独使用或者以药物组合物的形式使用;所述的药物组合物包含治疗有效量的Bepridil和/或KB-R7943,以及黑色素瘤常规化疗药物和治疗手段。
5.根据权利要求1所述的应用,其特征在于,将Bepridil或KB-R7943与其他常规化疗药物合并使用,可以增强黑色素瘤对其他常规化疗药物的敏感性。
6.根据权利要求4-5任一所述的应用,其特征在于,所述常规化疗药物包括但不限于:化学治疗药物达卡巴嗪、替莫唑胺、尼莫斯汀、卡莫斯汀、洛莫斯汀、甲基苄肼、甲氨喋呤或福莫司汀,生物治疗药物威罗菲尼、达拉菲尼、曲美替尼、易普利姆玛、nivolumab和pembrolizumab,小分子靶向药物BRAF抑制剂、MEK抑制剂、作用于程序性死亡分子1(PD-1)的免疫治疗药物;所述的治疗手段包括但不限于溶瘤病毒疗法。
7.一种治疗黑色素瘤的药物组合物,其特征在于,所述药物组合物是治疗有效量的Bepridil和/或KB-R7943,以及药学上可接受的载体。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010530779.3A CN111450089A (zh) | 2020-06-11 | 2020-06-11 | Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010530779.3A CN111450089A (zh) | 2020-06-11 | 2020-06-11 | Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111450089A true CN111450089A (zh) | 2020-07-28 |
Family
ID=71671872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010530779.3A Pending CN111450089A (zh) | 2020-06-11 | 2020-06-11 | Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111450089A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022854A (zh) * | 2020-09-18 | 2020-12-04 | 上海交通大学医学院 | Cb-dmb在制备治疗黑色素瘤的药物中的应用 |
CN113908145A (zh) * | 2021-09-18 | 2022-01-11 | 中国人民解放军陆军军医大学第二附属医院 | 2-[4-[(4-硝基苯基)甲氧基]苯基]乙基氨基亚氨基硫酸酯的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108066337A (zh) * | 2017-12-22 | 2018-05-25 | 上海交通大学医学院 | KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用 |
-
2020
- 2020-06-11 CN CN202010530779.3A patent/CN111450089A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108066337A (zh) * | 2017-12-22 | 2018-05-25 | 上海交通大学医学院 | KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用 |
Non-Patent Citations (2)
Title |
---|
BENJAMIN GALLANT 等: "Aberrant sodium current contributes to constitutive mTOR activity in malignant melanoma cells", 《CANCER RES》 * |
YI YANG 等: "mTOR-mediated Na+ /Ca2+ exchange affects cell proliferation and metastasis of melanoma cells", 《BIOMEDICINE & PHARMACOTHERAPY》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112022854A (zh) * | 2020-09-18 | 2020-12-04 | 上海交通大学医学院 | Cb-dmb在制备治疗黑色素瘤的药物中的应用 |
CN113908145A (zh) * | 2021-09-18 | 2022-01-11 | 中国人民解放军陆军军医大学第二附属医院 | 2-[4-[(4-硝基苯基)甲氧基]苯基]乙基氨基亚氨基硫酸酯的应用 |
CN113908145B (zh) * | 2021-09-18 | 2023-09-22 | 中国人民解放军陆军军医大学第二附属医院 | 2-[4-[(4-硝基苯基)甲氧基]苯基]乙基氨基亚氨基硫酸酯的应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101589026B (zh) | 治疗脑神经胶质瘤的方法 | |
KR101653071B1 (ko) | 선별적 s1p₁ 수용체 작동약에 대한 투약 섭생 | |
US6239172B1 (en) | Formulations for treating disease and methods of using same | |
US20210322407A1 (en) | Use of Trimetazidine in Preparation of Drugs for Preventing and Treating Liver Diseases | |
CN111450089A (zh) | Bepridil或KB-R7943在制备治疗黑色素瘤的药物中的应用 | |
AU2018392985A1 (en) | Compositions and methods of treatment for neurological disorders comprising motor neuron diseases | |
CN111346081B (zh) | 包含正戊酸、吲哚丙酸和正丁酸钠的药物组合物的新用途 | |
US20210353580A1 (en) | Application of chlorogenic acid and compositions thereof in preparation of drugs for treating squamous cell carcinoma | |
Goyagi et al. | Neuroprotective effects of selective beta-1 adrenoceptor antagonists, landiolol and esmolol, on transient forebrain ischemia in rats; a dose–response study | |
CN111701024B (zh) | 一种左旋多巴制剂及其制备方法及其应用 | |
US6992073B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for treating cervical erosion | |
CN108066337B (zh) | KB-R7943或Bepridil在制备治疗神经胶质瘤的药物中的应用 | |
Clarke, VdV, Blair, DM & Weber | Field trial of hycanthone (Etrenol Winthrop) in the treatment of urinary and intestinal bilharziasis | |
CN114522158B (zh) | 用于制备治疗肝癌药物的代谢物及其应用 | |
WO2022241985A1 (zh) | H1组胺受体拮抗剂在制备治疗神经胶质瘤的药物中的应用 | |
TWI776450B (zh) | 正丁基苯酞於促進脂肪褐變、以及預防或治療脂肪肝及相關肝病變之應用 | |
CN112022854A (zh) | Cb-dmb在制备治疗黑色素瘤的药物中的应用 | |
CN114588164A (zh) | 瑞马唑仑在预防围术期低体温和寒战中的应用 | |
CN110664807B (zh) | 一种具有协同抗黑色素瘤功效的药物组合物及其应用 | |
WO2019164010A1 (ja) | 膀胱がん用抗腫瘍剤および膀胱がんの処置方法 | |
CN113368106B (zh) | 艾托莫德用于防治特发性肺纤维化的药物中的用途 | |
HUT66832A (en) | A stimulator of vascular endothelial cells and use thereof | |
CN112826820B (zh) | Nlrp3抑制剂及其应用 | |
CN115475162B (zh) | 4-异丁基-2-吡咯烷酮在制备镇痛药物中的应用、一种镇痛药物 | |
CN113082025B (zh) | 二羟基苯甲酰胺衍生物在制备SerC抑制剂和抗结核药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200728 |